Assertio Therapeutics Announces Appointment of Dr. David Wheadon to its Board of Directors
“David is a globally recognized leader in healthcare and we are thrilled to have him join our Board of Directors,” said
“I am excited to serve on Assertio’s Board and contribute to its ongoing transformation into a leading diversified biopharmaceutical company,” said Dr. Wheadon.
Dr. Wheadon is a former senior executive of
Dr. Wheadon holds a M.D. from
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
This news release contains forward-looking statements. These statements involve inherent risks and uncertainties that could cause actual results to differ materially from those projected or anticipated, including risks outlined in the Company's public filings with the
Investor and Media Contact:
SVP, Investor Relations and Corporate Communications
Source: Assertio Therapeutics, Inc.
Minimum 15 minutes delayed.